Rockville, Md. — October 16, 2025 — Leads & Copy — Theriva™ Biologics (NYSE American: TOVX) has entered into a warrant inducement agreement with existing institutional investors for the immediate exercise of warrants to purchase up to 7,360,460 shares of common stock at a reduced exercise price of $0.54 per share, resulting in gross cash proceeds of approximately $4.0 million. The offer to exercise will remain open until 11:30 AM ET for up to an additional $0.4 million in gross proceeds. The company intends to use the net proceeds for working capital and general corporate purposes.
In consideration for the immediate exercise of the Existing Warrants, investors will receive new unregistered warrants to purchase up to an aggregate of 14,720,920 shares of common stock. The New Warrants will have an exercise price of $0.54 per share and will be initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained and will expire five years following the Approval Date. The closing is expected to occur on or about October 17, 2025, subject to customary closing conditions.
A.G.P./Alliance Global Partners acted as the exclusive financial advisor.
The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the common stock issuable upon their exercise, have not been registered under the Securities Act. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the New Warrants.
Theriva™ Biologics (NYSE American: TOVX), is focused on developing therapeutics designed to treat cancer and related diseases. The Company’s lead clinical-stage candidates are: (1) VCN-01 (zabilugene almadenorepvec); (2) SYN-004 (ribaxamase); and (3) SYN-020.
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
Source: Theriva Biologics, Inc.
